> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron Awarded Priority Review Voucher
- URL: https://www.fdaweb.com/regeneron-awarded-priority-review-voucher/
- Published: 2022-05-02T12:00:00.000Z
- Updated: 2026-09-14T17:42:58.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151718

*Federal Register* notice: FDA has issued Regeneron Pharmaceuticals a priority review voucher under its material threat medical countermeasure product program. The voucher was awarded after FDA determined that Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), indicated for treating infections caused by Zaire ebolavirus, met the program’s criteria. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-05-02/pdf/2022-09315.pdf?ref=fdaweb.com).